Efficacy and Safety of Precision Therapy in Refractory Tumor

NCT03239015 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Rare Tumor
Refractory Tumor

Interventions

DRUG: Gefitinib
DRUG: Erlotinib
DRUG: Afatinib
DRUG: Trastuzumab
DRUG: Oxazolidine
DRUG: Olaparib
DRUG: Everolimus
DRUG: Cabozantinib
DRUG: Vemurafenib
DRUG: Dabrafenib
DRUG: Palbociclib
DRUG: PD-1/L1 inhibitor plus anti-angiogenic agent

Sponsor

Baodong Qin